Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.4B | 1.2B | 1.1B | 847M | 748M |
| Gross Profit | 942M | 755M | 683M | 535M | 475M |
| Operating Income | 189M | 9M | 74M | 6M | -8M |
| EBITDA | 223M | 46M | 109M | 30M | 8M |
| Net Income | 178M | 14M | 91M | -2M | 5M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$317.20
+0.33% today
1Y Change
+25.05%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Penumbra, Inc. (PEN) is a Healthcare stock with a market cap of $12.77B and listed on NYSE. The stock last traded around $317.20 and up 25.1% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +17.5%, EPS growth of +1169.4%, a dividend yield of 0.0%. What stands out right now is revenue +17.5%, EPS +1169.4%, free cash flow +18.8% with operating margin 13.5% and ROIC 9.9%. Valuation already assumes a fairly strong business story at P/E 71.8 and price/sales 9.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PEN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PEN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PEN Max Drawdown
-21.44%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PEN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$747.6M
-11.8% YoY
FY Net Income
$5.3M
+363.9% YoY
Free Cash Flow
-$11.7M
+84.4% YoY
Revenue Growth
+17.5%
EPS Growth
+1169.4%
Gross Margin
67.1%
Net Margin
12.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.4B | 1.2B | 1.1B | 847M | 748M |
| Gross Profit | 942M | 755M | 683M | 535M | 475M |
| Operating Income | 189M | 9M | 74M | 6M | -8M |
| EBITDA | 223M | 46M | 109M | 30M | 8M |
| Net Income | 178M | 14M | 91M | -2M | 5M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 187M | 324M | 167M | 70M | 59M |
| Total Assets | 1.8B | 1.5B | 1.6B | 1.4B | 1.2B |
| Total Liabilities | 399M | 382M | 377M | 372M | 290M |
| Shareholder Equity | 1.4B | 1.2B | 1.2B | 999M | 954M |
| Total Debt | 220M | 223M | 234M | 236M | 174M |
| Net Debt | 33M | -101M | 67M | 166M | 114M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10M
+117.1% YoY
Capital Expenditures
21M
-9.8% YoY
Free Cash Flow
12M
+84.4% YoY
Key ratios
Gross Margin
67.1%
Operating Margin
13.5%
Net Margin
12.7%
ROE
13.4%
Debt / Equity
0.15x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.